Combined effects of compound C and biguanides/versipelostatin in cancer cells during glucose deprivation.

<p>(A) MTT assay. 786-O cells were treated with compound C and phenformin under normal (<i>upper</i>) or 10 mM 2DG stress (<i>lower</i>) conditions. Results shown are the means ± SD of quadruplicate determinations. (B) Isobologram analysis for combined effects of compound C and phenformin under 2DG stress conditions. (C, D) MTT assay. 786-O cells were treated with compound C and versipelostatin (C) or buformin (D) in the presence of 10 mM 2DG. Results shown are the means ± SD of quadruplicate determinations. (E) MTT assay. HT1080 cells were treated with 1 µM compound C and 10 µM phenformin during glucose withdrawal. Results shown are the means ± SD of duplicate determinations. (F) Reporter assay. HT1080 cells were transfected with pGRP78pro160-Luc and treated with compound C and phenformin for 18 h in the presence of 10 mM 2DG. Results shown are the means ± SD of quadruplicate determinations. (G) Immunoblot analysis. HT1080 cells were treated for 6 h with various concentration of phenformin in the presence (+) or absence (−) of 10 mM 2DG and 5 µM compound C. β-actin was used as a loading control. GF, glucose-free; CC, compound C; Phen, phenformin.